AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting real-world and clinical trial data for its gastroenterology drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ) in treating Crohn's disease and ulcerative colitis. The data demonstrated sustained symptom relief, improved quality of life, and lower hospitalization rates, reinforcing the drugs' efficacy, safety, and durability. Notably, risankizumab showed low treatment switch rates, and upadacitinib reduced hospitalizations compared to biologic dose escalation. These findings support AbbVie's leadership in advancing inflammatory bowel disease care and may influence future treatment guidelines and approvals.
Johnson & Johnson and AbbVie both exceeded Q1 2026 revenue expectations, prompting them to raise their full-year guidance. JNJ's growth was driven by diversified pharma and MedTech segments, notably TREMFYA and cardiovascular products, while AbbVie r...
A $1 million portfolio in high-yield dividend stocks generating $60,000 income faces a $14,400 annual tax bill at the 24% federal bracket if held in a taxable account. Placing these stocks in a Roth IRA avoids this tax, allowing the full income to gr...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and chil...
Replacing a $65,000 annual salary with dividends requires a portfolio yield strategy. At a conservative 3% yield, you'd need about $2.17 million, but at an aggressive 10% yield, $650,000 suffices. Conservative stocks like Coca-Cola offer stability bu...
AbbVie presented new data at the 2026 ASCO Annual Meeting showcasing its oncology pipeline targeting solid tumors and blood cancers. Key findings include promising results from antibody-drug conjugates (ADCs) and T-cell engagers in cancers like metas...
